Vanguard Group Inc Clearside Biomedical, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,839,978 shares of CLSD stock, worth $2.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,839,978
Previous 2,839,978
-0.0%
Holding current value
$2.5 Million
Previous $3.69 Million
2.3%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CLSD
# of Institutions
55Shares Held
12.2MCall Options Held
54.7KPut Options Held
50.7K-
Act Capital Management, LLC Wayne, PA2.2MShares$1.93 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.7 Million0.04% of portfolio
-
Black Rock Inc. New York, NY798KShares$702,3600.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$655,5020.0% of portfolio
-
Geode Capital Management, LLC Boston, MA731KShares$643,6190.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $53M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...